Photo of STA Office

Specialised Therapeutics Australia (STA) is a bio-pharmaceutical company dedicated to working with leading international pharmaceutical and diagnostic companies to provide patient access to innovative healthcare solutions.

STA Commercialises, with the Highest Professional and Ethical Standards, Innovative Therapies and Technologies that Uniquely Fulfil the Unmet Medical Needs of our Community.

March, 2014: Rare Cancers Australia - A focus on less common cancers

Two articles / reports on less common cancers from Rare Cancers Australia.

Read More

Jan, 2014: Updated Pancreatic Cancer Data Presented At International Cancer Conference

A leading breast cancer drug, ABRAXANE® (nanoparticle albumin-bound paclitaxel), has been shown to extend overall survival (OS) for patients with metastatic pancreatic cancer when used in combination with current standard of care, gemcitabine, with some patients surviving longer than three years.

Read More

Jun, 2013: Melbourne Biopharmaceutical Company Named First Corporate Sponsor of International Medical Aid Organisation

Melbourne biopharmaceutical company Specialised Therapeutics Australia has become the first corporate sponsor of an international charitable organisation which enables medical and surgical specialists to impart their expertise to colleagues in developing countries.

Read More

Nov, 2012: ABRAXANE Meets Primary Endpoint of Overall Survival Improvement in Phase III Advanced Pancreatic Cancer Study

Specialised Therapeutics Australia (STA) is pleased to announce that the phase III, randomised, international study of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in combination with gemcitabine in treatment-naïve patients with advanced pancreatic cancer met its primary endpoint of overall survival.

Read More

Oct, 2012: ABRAXANE Meets Primary Endpoint of Progression-Free Survival in Phase III Chemotherapy-Naïve Metastatic Melanoma Study

Specialised Therapeutics Australia (STA) is pleased to announce the results of the phase III, randomised, international study (CA033) of ABRAXANE® (nanoparticle albumin-bound paclitaxel) in chemotherapy-naïve patients with metastatic melanoma.

Read More

Sep 2015: TAILORx trial finds 99 percent of women with low Oncotype DX® Recurrence Score® results are free of breast cancer recurrence after five years of hormone therapy alone

The presentation of the first results from the Trial Assigning IndividuaLised Options for Treatment (Rx), or TAILORx, a large, prospectively conducted trial, designed and conducted by the ECOG-ACRIN Cancer Research Group under the sponsorship of the U.S. National Cancer Institute (NCI).

Read More

Sep 2015: Specialised Therapeutics’ Breakthrough Brain Tumour Visualisation Drug GLIOLAN® Approved For Use in New Zealand

A novel drug which helps neurosurgeons to better visualise and remove malignant brain tumours has been approved for marketing and distribution in New Zealand by Medsafe.

Read More

Sep 2015: Cutting Edge Breast Cancer Test ‘Should Be Reimbursed’ - Medical Experts

A BREAKTHROUGH genetic test that could spare thousands of Australian women with early stage breast cancer from chemotherapy and its toxic side effects will be considered for reimbursement later this year.

Read More

Aug 2015: License Agreement with PharmaMar to Market, Distribute Oncology Drug APLIDIN® (plitidepsin) in AU and NZ

STA has struck an exclusive license and commercialisation agreement with European pharmaceutical partner company PharmaMar to market and distribute the novel oncology drug APLIDIN® (plitidepsin) in Australia and New Zealand.

Read More